Role of nutraceutical «Resvega forte» in complex treatment of choroidal neovascularization caused by pathological myopia against the background of antiangiogenic therapy with ranibizumab
Authors:   The S. Fyodorov Eye Microsurgery Federal State Institution, the Khabarovsk Branch, Khabarovsk, Russian Federation, Danilova L.P. ,   Postgraduate Institute for Public Health Workers, Khabarovsk, Russian Federation, Egorov V.V. ,   The S. Fyodorov Eye Microsurgery Federal State Institution, the Khabarovsk Branch, Khabarovsk, Russian Federation,   Postgraduate Institute for Public Health Workers, Khabarovsk, Russian Federation, Smoliakova G.P. ,   The S. Fyodorov Eye Microsurgery Federal State Institution, the Khabarovsk Branch, Khabarovsk, Russian Federation,   Postgraduate Institute for Public Health Workers, Khabarovsk, Russian Federation, Povalyaeva D.А. ,   The S. Fyodorov Eye Microsurgery Federal State Institution, the Khabarovsk Branch, Khabarovsk, Russian Federation, Zhajvoronok N.S. ,   The S. Fyodorov Eye Microsurgery Federal State Institution, the Khabarovsk Branch, Khabarovsk, Russian Federation, Udovichenko Е.V. ,   The S. Fyodorov Eye Microsurgery Federal State Institution, the Khabarovsk Branch, Khabarovsk, Russian Federation, Emanova L.P. ,   The S. Fyodorov Eye Microsurgery Federal State Institution, the Khabarovsk Branch, Khabarovsk, Russian Federation
Published: April 2022

Purpose. Evaluation of clinical efficacy of nutraceutical «Resvega forte» in complex treatment of myopic choroidal neovascularization (CNV) against the background of antiangiogenic therapy with ranibizumab. Material and methods. 25 patients with CNV that developed against the background of pathological myopia. In patients of the main group (16 people), a single ranibizumab 0.5 mg intravitreal injection was supplemented the appointment of two courses of the “Resvega forte” complex, 1 capsule 2 times a day continuously for 3 months and then second course after 6 months at the same dosage. Patients of the comparison group (9 people) were not prescribed the “Resvega forte” complex. For objective diagnostic, the best corrected visual acuity (BCVA), retinal electric sensitivity threshold (EST) and electric lability (EL) of optic nerve, data of optical coherence tomography (OCT) and OCT-angiography (OCT-A) of the retina were evaluated. Study monitoring was performed within 12 months from the start of treatment. Indications for repeated ranibizumab intravitreal injections were persistence of CNV activity or its recurrence. Results. By the end of observation period (12 months), BCVA in patients of the main group was 0.57 ± 0.04, and in the comparison group – 0.21 ± 0.03. In patients of the main group, retinal EST decreased to 62.5 ± 1.5µA, and EL of optic nerve increased to 35.4 ± 1.3 Hz, while in the comparison group decrease in EST and increase in EL were less significant. The total number of intravitreal injections during 12 months of observation in patients of the main group was 2–3, while in the comparison group it was 5–6. Conclusion. At comparable morphometric characteristics of remission of pathological process without signs of activity of choroidal neovascular membrane by 12 months of observation in the main group, against the background of use “Resvega forte”, compared to the comparison group, increase in visual acuity by 3.5 times and increase number of patients with improved electrophysiological parameters by 1.3 times, were achieved. Keywords: pathological myopia, myopic choroidal neovascularization, ranibizumab, “Resvega forte”.